Rocket Pharma doses first patient in Phase 1 study of Danon treatment
Category: #health  By Mateen Dalal  Date: 2019-06-20
  • share
  • Twitter
  • Facebook
  • LinkedIn

Rocket Pharma doses first patient in Phase 1 study of Danon treatment

RP-A501 gene therapy can make a significant difference in patients who are suffering from Monogenic Heart Failure Syndrome

Rocket Pharmaceuticals Inc, a multi-platform clinical-stage gene therapy company based in the U.S., recently announced that they have commenced dosing patients in the open-label, Phase 1 clinical study of RP-A501, a gene therapy based on adeno-associated viral vector (AAV) that is developed to treat Danon disease.

Apparently, University of California San Diego (UCSD) Health is the lead and initial center for Phase 1 trial which is led by Barry Greenberg, Director of Advanced Heart Failure Treatment Program at UC San Diego Health and Professor of Medicine at UC San Diego School of Medicine and happens to be the trial’s principal investigator, along with Eric Adler, M.D., Director of Cardiac Transplant and Mechanical Circulatory Support at UCSD Health and Professor of Medicine at UCSD.

Chief Executive Officer and President of Rocket, Gaurav Shah, M.D., said that the Danon disease is a progressive cardiomyopathy wherein the company believes the gene therapy can make a significant difference in patient outcomes. The existing standards of care for Danon are not curative and are generally associated with certain morbidity and mortality.

Consequently, the age of 19 has been reported as the median survival age for male patients suffering for Danon disease, reportedly caused by heart failure, Shah said. This demands an urgent need for alternative options like RP-A501 gene therapy to address patients and families facing the fatal disease.

Dr. Adler said that the development of RP-A501 into clinic is an enormous step towards treating this fatal disease and rare cardiac disorders. UCSD Health is looking forward to being the first and lead center to hold RP-A501 Phase 1 clinical trial and it looks forward to rapidly advance it through the clinic for patients in need.

Apparently, the study is designed to specifically assess the tolerability and safety of RP-A501’s single infusion.

Source Credit- https://rocketpharmaceuticals.gcs-web.com/news-releases/news-release-details/rocket-pharmaceuticals-announces-patient-dosing-has-commenced

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Facebook and Instagram owner Meta to lay off 10,000 jobs to cut costs
Facebook and Instagram owner Meta to lay off 10,000 jobs to cut costs
By Mateen Dalal

Meta, the leading American technology company and the owner of social media platforms Facebook and Instagram, has reportedly announced its plans to lay off around 10,000 employees. Apparently, this is going to be the second round of significant la...

Heathrow to lower passenger charges to feed through to the ticket prices
Heathrow to lower passenger charges to feed through to the ticket prices
By Mateen Dalal

Heathrow Airport, the U.K.’s leading international airport, has reportedly been advised to reduce passenger costs for airlines next year, as they would have an impact on ticket pricing. The Civil Aviation Authority (CAA) determined that lowe...

Amazon signs deal with mortgage lender Better.com to give employee benefits
Amazon signs deal with mortgage lender Better.com to give employee benefits
By Mateen Dalal

Amazon, the U.S.-based e-commerce giant, has reportedly inked a deal with struggling mortgage lender, Better.com to provide better perks to employees. For the unversed, Better.com is introducing Equity Unlocker, a product that enables staff member...